1,242 filings
Page 6 of 63
6-K
SNY
Sanofi
29 Apr 22
Current report (foreign)
12:38pm
6-K
SNY
Sanofi
28 Apr 22
Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1
12:16pm
6-K
SNY
Sanofi
19 Apr 22
Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine
11:32am
6-K
SNY
Sanofi
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
SNY
Sanofi
4 Apr 22
Distribution of Shares of Euroapi
11:21am
6-K
SNY
Sanofi
1 Apr 22
French AMF approved EUROAPI’s listing prospectus
1:40pm
6-K
SNY
Sanofi
31 Mar 22
Current report (foreign)
12:12pm
6-K
SNY
Sanofi
30 Mar 22
Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
1:44pm
6-K
SNY
Sanofi
22 Mar 22
Sanofi and Seagen Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
2:29pm
6-K
SNY
Sanofi
15 Mar 22
Sanofi recognized by S&P as one of the most sustainability-committed companies
3:52pm
6-K
SNY
Sanofi
4 Mar 22
Current report (foreign)
4:20pm
6-K
SNY
Sanofi
24 Feb 22
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
5:14pm
IRAN
SNY
Sanofi
23 Feb 22
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
1:32pm
20-F
2021 FY
SNY
Sanofi
Annual report (foreign)
23 Feb 22
1:00pm
SC 13G/A
Amundi
22 Feb 22
Sanofi / Amundi ownership change
12:04pm
SC 13G/A
Amundi
15 Feb 22
Sanofi / Amundi ownership change
8:17am
6-K
SNY
Sanofi
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
SC 13G
SNY
Sanofi
14 Feb 22
Sanofi / DODGE & COX ownership change
1:29pm
SC 13G
ICVX
Icosavax Inc
8 Feb 22
Icosavax / Sanofi ownership change
8:27am
6-K
SNY
Sanofi
4 Feb 22
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
1:29pm